SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy.
This MOU was held on January 15th, local time, during JP Morgan Healthcare Conference (San Francisco, USA).
The two companies have been conducting combination therapy study of the immuno-oncology drug GI-102 and ADC LM-302 targeting Claudin18.2 and recently observed excellent anticancer activity in a preclinical pancreatic cancer model.
Both substances are in the clinical stage. GI-102 has completed phase 1 clinical trial in the US and Korea and can quickly enter phase 2. LM-302 is currently in phase 3 clinical trial for 3L and above gastric cancer in China. Pancreatic cancer has no approved immunotherapy, and the only approved treatment is a chemotherapy cocktail, but its treatment efficacy is low and its toxicity is high. Through this agreement, both companies will conduct clinical trial targeting patients with metastatic pancreatic cancer.
Dr. Myoung Ho Jang, CSO said, "We are delighted to be conducting a combination study with LaNova, which is recognized by global pharma companies. LaNova's ADC, which directly destroys tumor cells to increase the response rate, and GI-102, which can enhance immune memory to increase overall survival, are expected to be a combination therapy that can change the pancreatic cancer treatment paradigm."
"GI-102 exemplifies GI Innovation's robust R&D capabilities in immunotherapy. We are excited to explore its combination with LaNova's Claudin18.2 ADC, LM-302, which holds the potential to provide a novel therapeutic option for pancreatic cancer patients" Dr. Crystal Qin, LaNova CEO emphasized.
About GI Inovation
GI Innovation, a KOSDAQ-listed biotech, pioneers fusion protein drugs for cancer and allergies. Since 2017, it secured $230 million through funding rounds, IPO, and licensing deals for preclinical and clinical assets. Leveraging global partnerships for rapid development, the leading programs include immuno-oncology assets GI-101, subcutaneous form GI-102, and anti-allergy asset GI-301, metabolic immuno-oncology asset GI-108 alongside other innovative programs.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
PORT VILA, Vanuatu, Feb. 15, 2025 /PRNewswire/ -- Vantage Markets is proud to announce its success at the 5th Annual Business Tabloid Awards, held on 23rd January 2025 in Dubai. The Annual Business Tabloid Awards celebrate outstanding achievements across industries, including banking, finance, technology, and leadership. Winners are selected by a panel of industry experts, who evaluate nominees based on innovation, performance, and impact. Receiving three awards at this distinguished event reflects Vantage's global commitment to excellence in the financial services industry.
The event brought together industry leaders and influencers to celebrate excellence across various sectors, including banking, finance, technology, and trading. The evening commenced with a networking session, providing an invaluable opportunity for professionals to connect and exchange insights. Followed by the award presentation ceremony, where Vantage was honored for its excellence, reflecting its commitment to providing quality trading solutions.
Marc Despallieres, CEO of Vantage Markets, shared his thoughts on the achievement: "Winning these three awards at the Business Tabloid Awards is a testament to our commitment to excellence, innovation, and client-centricity. These accolades reflect the hard work of our team and the trust our clients place in us. We are proud to have been recognized for our excellence in APAC, LATAM, and MENA, reflecting our commitment to empowering our traders."
As Vantage continues to expand its presence and deliver value to its clients, the company is committed to maintaining its reputation for excellence and innovation.
For more information on Vantage's award-winning services, visit Vantage Markets.
About Vantage
Vantage Markets (or Vantage) is a multi-asset CFD broker offering clients access to a nimble and powerful service for trading Contracts for Difference (CFDs) products, including Forex, Commodities, Indices, Shares, ETFs, and Bonds.
With over 15 years of market experience, Vantage transcends the role of broker, providing a trusted trading ecosystem, an award-winning mobile trading app, and a user-friendly trading platform that empowers clients to seize trading opportunities. Download the Vantage App on App Store or Google Play.
trade smarter @vantage
Important Notice: This article is for informational purposes only and does not constitute an offer or solicitation of Vantage's services in any jurisdiction. Vantage's services may not be available in all regions mentioned and are subject to strict regulatory requirements. Before engaging with our services, please check your local regulations to ensure you are eligible to access our products and services in your region.
RISK WARNING: CFD trading carries significant risks. You could lose more than your initial investment.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Vantage Honored with Three Prestigious Awards at the 5th Annual Business Tabloid Awards
Vantage Honored with Three Prestigious Awards at the 5th Annual Business Tabloid Awards